HTATSF1 and neoplasm: Our study argues that targeting this axis in combination with PARPis or platinum drugs will benefit tumor patients with hyperactive CK2–HTATSF1–TOPBP1, and understanding the activity of this pathway may precisely guide the application of the CK2 inhibitor CX-4945, currently in clinical trials for various cancers (23).